Drug intelligence / Profile preview

jiedu qingwen decoction

Development stage: Preclinical
Lead developer: Guang'anmen Hospital
Administration: Oral

Overview

Jiedu Qingwen Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is primarily indicated for the treatment of influenza A, specifically targeting patients diagnosed with the 'external cold and internal heat' syndrome. The decoction is designed to clear heat, detoxify the body, and resolve exterior symptoms associated with viral respiratory infections. In clinical research, it has been evaluated in prospective cohort studies to compare its efficacy and safety against standard antiviral treatments such as oseltamivir, focusing on outcomes like fever duration and symptom resolution.

Other names: Jiedu Qingwen Tang

Targets

LY96 (Myeloid differentiation factor 2)

Beyond the preview

Go deeper on jiedu qingwen decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jiedu qingwen decoction.

Explore the full profile